FDA's Draft Guidance on Data Integrity for Bioavailability & Bioequivalence Studies, Sanofi's DCT Definition, and More

FDA's Draft Guidance on Data Integrity for Bioavailability & Bioequivalence Studies, Sanofi's DCT Definition, and More

Welcome to the Clinical Trial Insights newsletter, featuring strategic insights and expert opinions on designing and running clinical trials. Each edition covers the latest trending articles on ClinicalLeader.com.

In this week's issue, we'll explore the FDA's new draft guidance on maintaining data integrity throughout bioavailability/bioequivalence studies, what defines a DCT at Sanofi, how Regeneron's Digital Biomarkers Summit is bringing competitors together, what to consider when selecting an RTSM vendor, and other popular insights.

If you like what you're seeing in our condensed LinkedIn editions, subscribe to our daily newsletter for full access to exclusive articles, webinars, e-books, and more! Subscribe Now →


WEBINAR 06.11.24

Efficient Trials For Optimal Outcomes: Balancing Data, Technology, and Strategy in Clinical Research

In this webinar, Medrio CEO Nicole DuPont Latimer and Blue Parachute Group Founder & CEO Amy Longcore will uncover common pitfalls in trial data management, such as collecting insufficient or irrelevant data, and explore best practices for an effective data collection strategy and how to select technology to support your research needs.

REGISTER TODAY →


TOP 5 READS OF THE PAST WEEK

#1 - New FDA Draft Guidance: Data Integrity For In Vivo Bioavailability And Bioequivalence Studies

The FDA's new draft guidance emphasizes maintaining data integrity throughout bioavailability/bioequivalence studies and provides recommendations for applicants and testing site management. The public comment period ends July 3.

READ NOW →


#2 - What Makes Up A DCT At Sanofi?

In this snippet from Clinical Leader Live, Merissa Govender , Global Innovation Leader at Sanofi , explains how the company defines a DCT and what therapeutic areas they focus on for these kinds of trials.

WATCH NOW →


#3 - Competitors Need To Collaborate On Digital Biomarkers

The pharma industry isn’t known for collaboration, but Regeneron is trying to change that — at least as far as digital biomarkers are concerned. Chief Editor Dan Schell caught up with Rinol Alaj to learn more about why Regeneron is producing their Digital Biomarkers Summit.

READ NOW →


#4 - What Should Be Considered When Selecting An RTSM Vendor?

Keep these insights in mind when choosing an RTSM technology and vendor to ensure both your technology aligns with your business's growth and your partner is committed to your success.

READ NOW →


#5 - The Best Advice I Ever Got: On The Job

To commemorate Clinical Trials Day 2024, Clinical Leader's Abby Proch tapped our community of clinical research professionals to share their insights — from individual efforts to partnership best practices to trial design and more.

READ NOW →



MORE TO EXPLORE


Clinical Leader is an online community serving professionals in the clinical research space. We share insights and best practices — from industry experts — to help sponsors and CROs tackle the biggest challenges they face in designing and running clinical trials.

To get the most out of our offerings, join the Clinical Leader community.

要查看或添加评论,请登录

社区洞察

其他会员也浏览了